Charting a course to intercepting Type I diabetes

Arguably, the most important innovations on the horizon for Type I diabetes would replace the insulin-producing cells patients have lost or prevent at-risk individuals from losing the cells in the first place. With Provention planning a rolling BLA submission this year for a treatment meant to intercept Type I diabetes before it starts, the latter approach could be taking off first.

Johnson & Johnson (NYSE:JNJ) is behind Provention Bio Inc. (NASDAQ:PRVB) in the interception setting, and Imcyse S.A. may follow in its footsteps after it generates early stage data in the treatment setting. After diagnosis, patients with Type I diabetes are wedded to careful glucose monitoring and frequent insulin injections their whole life. ...